Comparison of conbercept and ranibizumab combined mitomycin C-augmented trabeculectomy for neovascular glaucoma
International Ophthalmology · 2021-08 · 41 (8) · 2869-2877
DOI: 10.1007/s10792-021-01846-6 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Ophthalmology, online erschienen am 24.04.2021. Verfasst von Xiaohong Guo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Ningbo Eye Hospital, No. 599 Beimingcheng Road, Yinzhou District, Ningbo, 315000, Zhejiang Province, China. Hauptthemen laut MEDLINE: Glaucoma, Neovascular, Trabeculectomy. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 22 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: To compare the efficacy and security of conbercept and ranibizumab combined with trabeculectomy and panretinal photocoagulation for neovascular glaucoma (NVG). METHODS: One hundred and sixty patients with NVG were randomly divided into a conbercept group comprised of 80 patients and a ranibizumab group comprised of 80 patients. The postoperative and preoperative visual acuities, intraocular pressures frequency of anti-glaucoma medications, and surgical complications were recorded. The expressions of vascular endothelial growth factor (VEGF), vascular endothelial growth factor receptor (FLT-1), and placenta-like growth factor (PLGF) in the aqueous humor were determined using an enzyme-linked immunosorbent assay. Examining the fundus and obtaining photographs used indirect ophthalmoscopy. Kaplan-Meier and log-rank analyses estimated the success rates. RESULTS: All patient follow-up periods were at 1 year. The differences observed in IOP and the frequencies of anti-glaucoma medications at various follow-up time points were not statistically significant (all P > 0.05). The differences observed in both the group visual acuities at various follow-up time points were not statistically significant (P > 0.05). Rates of surgery complications were 18.75% and 25.00% in the conbercept group and ranibizumab group, respectively. The expressions of VEGF, FLT-1, and PLGF significantly decreased (all P < 0.05). The recurrence percentages were 30.00% and 36.25% after conbercept and ranibizumab treatment, respectively. CONCLUSION: The conbercept effects were similar with that of ranibizumab. Intravitreal injection of conbercept was effective for NVG treatment, which provides a new therapeutic drug for NVG treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Ophthalmology, Ningbo Eye Hospital, No. 599 Beimingcheng Road, Yinzhou District, Ningbo, 315000, Zhejiang Province, China.
- Department of Ophthalmology, Ningbo Eye Hospital, No. 599 Beimingcheng Road, Yinzhou District, Ningbo, 315000, Zhejiang Province, China. wuyuemrs@163.com.
Zitieren
APA
Guo, X., Wang, Y., Yang, L., Wang, P., Chen, K., Zhou, L., & Wu, Y. (2021). Comparison of conbercept and ranibizumab combined mitomycin C-augmented trabeculectomy for neovascular glaucoma. International Ophthalmology, 41(8), 2869-2877. https://doi.org/10.1007/s10792-021-01846-6
Vancouver
Guo X, Wang Y, Yang L, Wang P, Chen K, Zhou L, et al. Comparison of conbercept and ranibizumab combined mitomycin C-augmented trabeculectomy for neovascular glaucoma. International Ophthalmology. 2021;41(8):2869-2877. doi:10.1007/s10792-021-01846-6
BibTeX
@article{Guo2021,
author = {Guo, Xiaohong and Wang, Yuwen and Yang, Liangyan and Wang, Pengyun and Chen, Kan and Zhou, Lei and Wu, Yue},
title = {Comparison of conbercept and ranibizumab combined mitomycin C-augmented trabeculectomy for neovascular glaucoma},
journal = {International Ophthalmology},
year = {2021},
volume = {41},
number = {8},
pages = {2869--2877},
doi = {10.1007/s10792-021-01846-6}
}
EUVIMED